Zambon to Attend the CHEST Annual Meeting 2022
Retrieved on:
fredag, oktober 14, 2022
T cell, Amyotrophic lateral sclerosis, Autoimmune disease, Respiratory tract, Lung, BOS, Liposome, Inhalation, European Medicines Agency, Cleveland Clinic, American College, Urinary tract infection, Degenerative disease, Regulation of tobacco by the U.S. Food and Drug Administration, American College of Chest Physicians, Phenotype, Parkinson's disease, Pain management, ALS, Respiratory system, Inflammation, Cystic fibrosis, Company, CE, Riluzole, CMO, FDA, Pathology, Disease, Diagnosis, Critical Care Medicine (journal), CME, Stanford University, Death, CLAD, Life, MOC, Education, Patient, Orphan drug, Food, Immune system, Medicare, MD, Health, Convention, Safety, Fast Track, Obliterative bronchiolitis, Bronchiole, Pharmaceutical industry, Dentistry, Medical device, Zambon
In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.
Key Points:
- In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.
- This event is not part of the official CHEST Annual Meeting 2022 conference sessions.
- This event is not endorsed by CHEST and does not reflect the views or opinions of CHEST.
- In Europe, Zambon also plans to market and distribute, upon regulatory approval, an innovative oral formulation of riluzole for patients suffering with Amyotrophic Lateral Sclerosis (ALS).